McKesson (MCK Quick QuoteMCK - Free Report) reported strong fourth-quarter fiscal 2026 results, driven by robust growth in specialty distribution, oncology services and biopharma solutions. Earnings expansion benefited from ongoing operational efficiency and capital discipline, despite persistent margin pressures and volatility across certain segments.

Shares of this Zacks Rank #3 (Hold) company have lost 6.6% so far this year compared with the industry's 9.3% decline. The S&P 500 has increased 9.2% in the said time frame.

MCK is one of the leading pharmaceutical distributors in North America, with a market capitalization of $90.72 billion. It forecasts 13.2% growth in fiscal 2027 and aims to sustain its strong performance going forward. The company’s earnings surpassed estimates in each of the trailing four quarters, the average beat being 3.09%.

Image Source: Zacks Investment Research

Factors Favoring MCK Stock

Oncology and Multispecialty Platform Become a High-Growth Engine: McKesson’s oncology and multispecialty business is increasingly emerging as the company’s primary structural growth driver, with segment revenues rising 35% in the fourth quarter of fiscal 2026 and operating profit surging 53%.

Excluding acquisitions, organic operating profit still increased a solid 13%, highlighting sustained underlying demand rather than acquisition-driven growth alone. Expansion continues to be driven by provider additions, specialty drug distribution and greater integration of technology and analytics capabilities through Ontada and AI-enabled physician tools.

With the U.S. Oncology Network adding more than 570 providers in fiscal 2026, the largest increase since 2010, McKesson is building a scaled community-care ecosystem that strengthens both distribution economics and recurring service revenues.

Strong Specialty Pharmaceutical Momentum: McKesson continues to benefit from secular growth in specialty pharmaceuticals, particularly oncology, biologics and GLP-1 therapies, which remain among the fastest-growing categories in healthcare. In the fiscal fourth quarter, North American Pharmaceutical operating profit increased 11%, supported by specialty distribution growth and health system demand despite branded drug pricing pressure.

GLP-1 distribution revenues reached $14 billion in the quarter, up 22% year over year, underscoring the scale of the category. Management emphasized that lower branded pricing and sequential GLP-1 moderation had no operating profit impact, demonstrating the resilience of McKesson’s fee-based economics. This strengthens visibility into long-term earnings growth even amid drug pricing volatility.

Prescription Technology Solutions Holds Potential: McKesson’s Prescription Technology Solutions (RxTS) business is benefiting from rising drug complexity, affordability challenges and prior authorization requirements, particularly for specialty medications and GLP-1 therapies. The segment revenues increased 12% in the fiscal fourth quarter, while operating profit grew 13%, driven by robust demand for access and affordability services.

Management highlighted support for 3.4 million patients during the annual verification season, alongside rising productivity driven by automation and AI initiatives. McKesson also launched an integrated specialty access platform that combines benefits verification, prior authorization and affordability support within a single workflow.

As healthcare administration becomes increasingly complex, McKesson’s scale and digital connectivity are strengthening its competitive moat, which should help sustain double-digit profit growth.

Factors That May Offset the Gains for MCK

IRA-Driven Drug Pricing Pressure Creates Top-Line Headwinds: McKesson faces growing exposure to pharmaceutical pricing reform, particularly through the Inflation Reduction Act (IRA) and branded drug price reductions. Management disclosed that manufacturer price declines reduced North American Pharmaceutical revenue growth by approximately 3 percentage points in the fourth quarter of fiscal 2026, with additional pressure expected in fiscal 2027.

While the company emphasized that distribution economics remain intact due to fee-based contracts, sustained price compression could suppress reported revenue growth and reduce investor perception of underlying business momentum. Since McKesson distributes high-dollar specialty therapies, lower drug prices can materially affect top-line performance even when operating profits remain resilient.

Medical-Surgical Business Faces Margin and Growth Constraints: McKesson’s Medical-Surgical Solutions segment continues to underperform relative to its faster-growing specialty platforms. The fiscal fourth-quarter operating profit declined 5%, led by weaker illness-season demand, including vaccines and diagnostic testing, while revenues increased only 1%.

Although the planned separation unlocked value, the business remains exposed to lower-growth ambulatory care channels, product demand cyclicality and operational execution risks during carve-out. Management expects operating profit in fiscal 2027 to be flat to up only 4%, suggesting continued profitability constraints. Execution missteps during separation or weaker-than-expected standalone performance could reduce shareholder value creation.

RxTS Growth Becoming Less Predictable: While Prescription Technology Solutions continues to be a high-growth segment, management noted rising earnings volatility due to pharmaceutical launch timing, payer utilization trends, formulary shifts, and program transitions. The segment’s 3PL operations represent about 55% of total revenue, making quarterly results sensitive to new drug introductions and changes in manufacturer support programs.

Management also cautioned that fiscal 2027 revenue and operating trends may not progress linearly, adding near-term uncertainty despite strong long-term growth drivers. As therapies mature or move into lower-support phases, growth may become more uneven and harder to predict.

Estimate Trends for MCK

McKesson is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings per share has improved 3 cents to $44.29.

The Zacks Consensus Estimate for the company’s first-quarter fiscal 2027 revenues and earnings per share is pegged at $104.95 billion and $9.48, respectively. The estimate for revenues indicates a 7.3% improvement from the year-ago quarter’s reported number, while that for earnings implies a 14.8% gain.

McKesson Corporation Price

McKesson Corporation price | McKesson Corporation Quote

Stocks to Consider

Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB Quick QuotePACB - Free Report) , Globus Medical (GMED Quick QuoteGMED - Free Report) and Biodesix (BDSX Quick QuoteBDSX - Free Report) .

Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.

Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.

Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.